Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
PaperCitations, authors & open-access status
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 78 citations, 2025 year and closed oa status.
78
Citations
2025
Year
closed
OA Status